Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study

Biologic Therapies for Severe Asthma

(2022) Guy G. Brusselle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma

(2021) Katrien Eger et al.   Journal of Allergy and Clinical Immunology-In Practice

Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)

(2021) Wendy C. Moore et al.   EUROPEAN RESPIRATORY JOURNAL

Defining a Severe Asthma Super-Responder: Findings from a Delphi Process

(2021) John W. Upham et al.   Journal of Allergy and Clinical Immunology-In Practice

Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study

(2021) Takanori Numata et al.   Journal of Asthma and Allergy

The association between control level and self-reported treatment adherence across different treatment types in Japanese asthma patients

(2021) Yasuhiro Gon et al.   Respiratory Investigation

Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study

(2021) Michael E Wechsler et al.   Lancet Respiratory Medicine

Real-World Effectiveness and the Characteristics of a “Super-Responder” to Mepolizumab in Severe Eosinophilic Asthma

(2020) Joanne E. Kavanagh et al.   CHEST

Effectiveness and safety of dupilumab for the treatment of severe asthma in a real‐life French multi‐centre adult cohort

(2020) Clairelyne Dupin et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Universal Masking in Hospitals in the Covid-19 Era

(2020) Michael Klompas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study

(2020) Yuji Tohda et al.   ALLERGOLOGY INTERNATIONAL

Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study

(2020) Takanori Numata et al.   BMC Pulmonary Medicine

Trends in Hospitalizations for Asthma During the COVID-19 Outbreak in Japan

(2020) Kazuhiro Abe et al.   Journal of Allergy and Clinical Immunology-In Practice

Severe asthma in Japan

(2019) Hiroyuki Nagase   ALLERGOLOGY INTERNATIONAL

Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan

(2019) Hiroyuki Nagase et al.   ALLERGOLOGY INTERNATIONAL

Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial

(2019) Hector Ortega et al.   Allergy Asthma and Clinical Immunology

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

(2019) Claus Bachert et al.   LANCET

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis

(2019) Takanori Numata et al.   BMC Pulmonary Medicine

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

(2018) Klaus F. Rabe et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

(2018) Mario Castro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Asthma control and quality of life in a real-life setting: a cross-sectional study of adult asthma patients in Japan (ACQUIRE-2)

(2018) Mitsuru Adachi et al.   JOURNAL OF ASTHMA

Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

(2017) Parameswaran Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

Severe and Difficult-to-Treat Asthma in Adults

(2017) Elliot Israel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Japanese guidelines for adult asthma 2017

(2017) Masakazu Ichinose et al.   ALLERGOLOGY INTERNATIONAL

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

(2016) Eugene R Bleecker et al.   LANCET

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

(2016) J Mark FitzGerald et al.   LANCET

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

(2016) Eric L. Simpson et al.   NEW ENGLAND JOURNAL OF MEDICINE

The prevalence of severe refractory asthma

(2015) Pieter-Paul W. Hekking et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

(2015) Mario Castro et al.   Lancet Respiratory Medicine

Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study

(2015) David B Price et al.   Lancet Respiratory Medicine

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

(2014) Elisabeth H. Bel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

(2014) Hector G. Ortega et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia

(2013) Michel Laviolette et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Targeting eosinophils in allergy, inflammation and beyond

(2013) Patricia C. Fulkerson et al.   NATURE REVIEWS DRUG DISCOVERY

The minimally important difference of the Asthma Control Test

(2009) Michael Schatz et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY